June 2025 Cancer Research Funding Landscape
Global cancer research funding reached an estimated $245 billion in 2024, with public and private sectors continuing to increase allocations. The National Cancer Institute (NCI) budget for fiscal year 2024 totaled approximately $7.2 billion, focusing on early detection and immunotherapy. Private foundations, including the Cancer Research Institute and the Leukemia & Lymphoma Society, contributed over $3.8 billion in grants during the same period. June 2025 data shows a 6.4% year-over-year increase in venture capital flowing into oncology startups, driven by advances in CAR-T cell therapy and mRNA cancer vaccines. Major pharmaceutical companies like Pfizer and Merck allocated over $18 billion combined to oncology R&D in 2024, with June pipeline reviews highlighting 47 new Phase III trials. For detailed funding breakdowns, see the Forbes analysis on cancer research investment trends.
The U.S. Food and Drug Administration (FDA) approved 12 new oncology drugs in 2024, with accelerated approvals accounting for 5 of them. June 2025 preliminary data indicates 8 additional therapies are under priority review, targeting solid tumors and hematologic malignancies. The FDA's Oncology Center of Excellence expedited 34 combination therapy trials in Q1 2025 alone. Biotech firms such as Moderna and BioNTech secured $1.2 billion in combined funding for personalized cancer vaccines during the first half of 2025. Government grants through the Cancer Moonshot initiative, relaunched in 2023, distributed $2.1 billion to 130 research institutions by mid-2025. The SEC EDGAR database provides public filings detailing these corporate oncology investments.
Clinical Trials and Treatment Advances in June 2025
ClinicalTrials.gov listed 5,812 active cancer-related interventional trials as of June 2025, with 1,240 new studies added in the first five months of the year. Immunotherapy trials account for 38% of all active oncology studies, followed by targeted therapy at 29% and cell therapy at 12%. The most frequently tested combination involves PD-1 inhibitors with chemotherapy, appearing in 612 trials globally. June 2025 data shows a 22% increase in trials for early-stage breast cancer detection using liquid biopsies. Companies like Guardant Health and Foundation Medicine lead the commercial deployment of these genomic tests, with combined revenues exceeding $1.4 billion in 2024. The National Cancer Institute clinical trials portal offers a searchable database of these ongoing studies.
CAR-T cell therapy expanded significantly, with 8 new FDA-approved products in development as of June 2025. Current approved therapies include tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta), which achieved combined global sales of $3.1 billion in 2024. June pipeline data indicates 14 bispecific T-cell engagers (BiTEs) are in Phase II trials for acute lymphoblastic leukemia. The cost of CAR-T treatment remains high, averaging $373,000 per infusion in the U.S., though newer autologous products are reducing manufacturing timelines to under 14 days. The